237 filings
Page 4 of 12
6-K
vm579dm7s67wdr0bhc
12 Oct 21
Results of Galmed’s Phase 2b ARREST Trial of Aramchol Published in Nature Medicine
7:00am
6-K
cw0qtful
31 Aug 21
Current report (foreign)
4:30pm
6-K
0166d8tv26rkwu bbpa5
23 Aug 21
Current report (foreign)
4:30pm
6-K
wzukpk2dd2rmbgq1
19 Aug 21
Galmed Pharmaceuticals Announces Publication in “The Journal of Autoimmunity” for its IND ready, Amilo-5MER, a specific anti-inflammatory compound
8:11am
6-K
hcr2 g210
16 Aug 21
MHRA Agrees with Galmed’s Plan to use Aramchol meglumine in the Randomized Double-blind Placebo-Controlled Part of the Phase 3 ARMOR study
8:31am
6-K
7o3wc99 a1qj0d
5 Aug 21
Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2021 Financial Results
7:00am
6-K
neu57ii4ywt
2 Aug 21
FDA Agrees with Galmed’s Plan to use Aramchol Meglumine in the Randomized Double-Blind Placebo-Controlled Part of the Phase 3 ARMOR study
7:47am
6-K
ntxa3lu 68
19 Jul 21
Current report (foreign)
4:30pm
6-K
7n5zad 3dj8
2 Jul 21
Current report (foreign)
4:30pm
6-K
yijwo5lb2u2
13 May 21
Galmed Pharmaceuticals Provides Business Updates and Reports First Quarter 2021 Financial Results
8:13am
6-K
nelr4h4s oskg
3 May 21
China to Join Galmed's Phase 3 ARMOR Registrational Study for the Treatment of NASH & Fibrosis
8:42am
EFFECT
o7xk abuw0
2 Apr 21
Notice of effectiveness
12:15am
CORRESP
suiaf8
1 Apr 21
Correspondence with SEC
12:00am
UPLOAD
zshu px44nn4kqhj6mf6
31 Mar 21
Letter from SEC
12:00am
6-K
f3tre1
26 Mar 21
Current report (foreign)
5:11pm
F-3
65mjftycaog3vxq
26 Mar 21
Shelf registration (foreign)
4:15pm
6-K
cq786 1dop46jog2f5bn
18 Mar 21
Galmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2020 Financial Results
7:29am
6-K
yknr896635qut
16 Mar 21
Galmed Pharmaceuticals Announces Dosing of First Subject in First in Human Phase 1 Trial of Amilo-5MER
8:38am
6-K
o4pxe07
18 Feb 21
Galmed Pharmaceuticals Announces Pricing of $10 Million Public Offering of Ordinary Shares
9:26am